RVL Pharmaceuticals plc operates as a specialized pharmaceutical firm, concentrating on the creation and commercialization of medicinal products. These offerings target patient populations with unmet needs within the fields of ocular health and medical aesthetics across the United States, Argentina, and Hungary. Among its key commercialized products is Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution specifically developed for adults experiencing acquired blepharoptosis, or drooping eyelids.